Discovery of Zafirlukast as a novel SARS-CoV-2 helicase inhibitor using in silico modelling and a FRET-based assay

References

• V.C. Cheng, S.K. Lau, P.C. Woo, and K.Y. Yuen, Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection, Clin. Microbiol. Rev. 20 (2007), pp. 660–694.
   PubMed Web of Science ®Google Scholar
• N. Lee, D. Hui, A. Wu, P. Chan, P. Cameron, G.M. Joynt, A. Ahuja, M.Y. Yung, C.B. Leung, K.F. To, S.F. Lui, C.C. Szeto, S. Chung, and J.J. Sung, A major outbreak of severe acute respiratory syndrome in Hong Kong, N. Engl. J. Med. 348 (2003), pp. 1986–1994. doi:https://doi.org/10.1056/NEJMoa030685.
   PubMed Web of Science ®Google Scholar
• A.M. Zaki, S. Van Boheemen, T.M. Bestebroer, A.D. Osterhaus, and R.A. Fouchier, Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, N. Engl. J. Med. 367 (2012), pp. 1814–1820. doi:https://doi.org/10.1056/NEJMoa1211721.
   PubMed Web of Science ®Google Scholar
• R.J. de Groot, S.C. Baker, R.S. Baric, C.S. Brown, C. Drosten, L. Enjuanes, R.A. Fouchier, M. Galiano, A.E. Gorbalenya, Z.A. Memish, S. Perlman, L.L. Poon, E.J. Snijder, G.M. Stephens, P.C. Woo, A.M. Zaki, M. Zambon, and J. Ziebuhr, Middle East respiratory syndrome coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group, J. Virol. 87 (2013), pp. 7790–7792. doi:https://doi.org/10.1128/JVI.01244-13.
   PubMed Web of Science ®Google Scholar
• P. Zhou, X.L. Yang, X.G. Wang, B. Hu, L. Zhang, W. Zhang, H.R. Si, Y. Zhu, B. Li, C.L. Huang, H.D. Chen, J. Chen, Y. Luo, H. Guo, R.D. Jiang, M.Q. Liu, Y. Chen, X.R. Shen, X. Wang, X.S. Zheng, K. Zhao, Q.J. Chen, F. Deng, L.L. Liu, B. Yan, F.X. Zhan, Y.Y. Wang, G.F. Xiao, and Z.L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature 579 (2020), pp. 270–273. doi:https://doi.org/10.1038/s41586-020-2012-7.
   PubMed Web of Science ®Google Scholar
• C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, and B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (2020), pp. 497–506. doi:https://doi.org/10.1016/S0140-6736(20)30183-5.
   PubMed Web of Science ®Google Scholar
• Y.A. Helmy, M. Fawzy, A. Elaswad, A. Sobieh, S.P. Kenney, and A.A. Shehata, The COVID-19 pandemic: A comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control, J. Clin. Med. 9 (2020), pp. 1225. doi:https://doi.org/10.3390/jcm9041225.
   PubMed Web of Science ®Google Scholar
• I. Astuti, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response, Diabetes Metab. Syndr. 14 (2020), pp. 407–412. doi:https://doi.org/10.1016/j.dsx.2020.04.020.
   PubMed Web of Science ®Google Scholar
• P. V’kovski, A. Kratzel, S. Steiner, H. Stalder, and V. Thiel, Coronavirus biology and replication: Implications for SARS-CoV-2, Nat. Rev. Microbiol. 19 (2021), pp. 155–170. doi:https://doi.org/10.1038/s41579-020-00468-6.
   PubMed Web of Science ®Google Scholar
• J.D. Twomey, S. Luo, A.Q. Dean, W.P. Bozza, A. Nalli, and B. Zhang, COVID-19 update: The race to therapeutic development, Drug Resist. Updates 53 (2020), pp. 100733. doi:https://doi.org/10.1016/j.drup.2020.100733.
   PubMed Web of Science ®Google Scholar
• A. Saxena, Drug targets for COVID-19 therapeutics: Ongoing global efforts, J. Biosci. 45 (2020), pp. 87.
   PubMed Web of Science ®Google Scholar
• A. Zumla, J.F. Chan, E.I. Azhar, D.S. Hui, and K.Y. Yuen, Coronaviruses - drug discovery and therapeutic options, Nat. Rev. Drug Discov. 15 (2016), pp. 327–347.
   PubMed Web of Science ®Google Scholar
• S.J. Macalino, V. Gosu, S. Hong, and S. Choi, Role of computer-aided drug design in modern drug discovery, Arch. Pharm. Res. 38 (2015), pp. 1686–1701. doi:https://doi.org/10.1007/s12272-015-0640-5.
   PubMed Web of Science ®Google Scholar
• G. Li and E. De Clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat. Rev. Drug Discov. 19 (2020), pp. 149–150. doi:https://doi.org/10.1038/d41573-020-00016-0.
   PubMed Web of Science ®Google Scholar
• L. Hage-Melim, L.B. Federico, N. de Oliveira, V. Francisco, L.C. Correia, H.B. De Lima, S.Q. Gomes, M.P. Barcelos, I. Francischini, and C. Da Silva, Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19, Life Sci. 256 (2020), pp. 117963. doi:https://doi.org/10.1016/j.lfs.2020.117963.
   PubMed Web of Science ®Google Scholar
• S. Pushpakom, F. Iorio, P.A. Eyers, K.J. Escott, S. Hopper, A. Wells, A. Doig, T. Guilliams, J. Latimer, C. McNamee, A. Norris, P. Sanseau, D. Cavalla, and M. Pirmohamed, Drug repurposing: Progress, challenges and recommendations, Nat. Rev. Drug. Discov. 18 (2019), pp. 41–58. doi:https://doi.org/10.1038/nrd.2018.168.
   PubMed Web of Science ®Google Scholar
• R.T. Eastman, J.S. Roth, K.R. Brimacombe, A. Simeonov, M. Shen, S. Patnaik, and M.D. Hall, Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19, ACS Cent. Sci. 6 (2020), pp. 672–683. doi:https://doi.org/10.1021/acscentsci.0c00489.
   PubMed Web of Science ®Google Scholar
• T. Polgár and G.M. Keseru, Integration of virtual and high throughput screening in lead discovery settings, Comb. Chem. High Throughput Screen. 14 (2011), pp. 889–897. doi:https://doi.org/10.2174/138620711797537148.
   PubMed Web of Science ®Google Scholar
• M. Rumlová and T. Ruml, In vitro methods for testing antiviral drugs, Biotechnol. Adv. 36 (2018), pp. 557–576.
   PubMed Web of Science ®Google Scholar
• K.G. Andersen, A. Rambaut, W.I. Lipkin, E.C. Holmes, and R.F. Garry, The proximal origin of SARS-CoV-2, Nat. Med. 26 (2020), pp. 450–452. doi:https://doi.org/10.1038/s41591-020-0820-9.
   PubMed Web of Science ®Google Scholar
• N. Kaur, R. Singh, Z. Dar, R.K. Bijarnia, N. Dhingra, and T. Kaur, Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2, Infect. Genet. Evol. 89 (2021), pp. 104490. doi:https://doi.org/10.1016/j.meegid.2020.104490.
   PubMed Web of Science ®Google Scholar
• J.S. Morse, T. Lalonde, S. Xu, and W.R. Liu, Learning from the past: Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV, Chembiochem 21 (2020), pp. 730–738. doi:https://doi.org/10.1002/cbic.202000047.
   PubMed Web of Science ®Google Scholar
• D.C. Hall Jr and H.F. Ji, A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease, Travel. Med. Infect. Dis. 35 (2020), pp. 101646. doi:https://doi.org/10.1016/j.tmaid.2020.101646.
   PubMed Web of Science ®Google Scholar
• R. Arya, S. Kumari, B. Pandey, H. Mistry, S.C. Bihani, A. Das, V. Prashar, G.D. Gupta, L. Panicker, and M. Kumar, Structural insights into SARS-CoV-2 proteins, J. Mol. Biol. 433 (2021), pp. 166725. doi:https://doi.org/10.1016/j.jmb.2020.11.024.
   PubMed Web of Science ®Google Scholar
• R. Gowthaman, J.D. Guest, R. Yin, J. Adolf-Bryfogle, W.R. Schief, and B.G. Pierce, CoV3D: A database of high resolution coronavirus protein structures, Nucleic Acids Res. 49 (2021), pp. D282–D287. doi:https://doi.org/10.1093/nar/gkaa731.
   PubMed Web of Science ®Google Scholar
• M.I. Ionescu, An overview of the crystallized structures of the SARS-CoV-2, Protein J. 39 (2020), pp. 600–618. doi:https://doi.org/10.1007/s10930-020-09933-w.
   PubMed Web of Science ®Google Scholar
• T.M. Lohman and K.P. Bjornson, Mechanisms of helicase-catalyzed DNA unwinding, Annu. Rev. Biochem. 65 (1996), pp. 169–214. doi:https://doi.org/10.1146/annurev.bi.65.070196.001125.
   PubMed Web of Science ®Google Scholar
• G.W. Owttrim, RNA helicases: Diverse roles in prokaryotic response to abiotic stress, RNA Biol. 10 (2013), pp. 96–110. doi:https://doi.org/10.4161/rna.22638.
   PubMed Web of Science ®Google Scholar
• K. Geider and H. Hoffmann-Berling, Proteins controlling the helical structure of DNA, Annu. Rev. Biochem. 50 (1981), pp. 233–260. doi:https://doi.org/10.1146/annurev.bi.50.070181.001313.
   PubMed Web of Science ®Google Scholar
• Z. Xing, W.K. Ma, and E.J. Tran, The DDX5/Dbp2 subfamily of DEAD-box RNA helicases, Wiley Interdiscip Rev RNA 10 (2019), pp. e1519. doi:https://doi.org/10.1002/wrna.1519.
   PubMed Web of Science ®Google Scholar
• R.M. Brosh Jr. and S.W. Matson, History of DNA helicases, Genes (Basel) 11 (2020), pp. 255. doi:https://doi.org/10.3390/genes11030255.
   Web of Science ®Google Scholar
• S. Aarattuthodiyil, A.K. Byrd, and K.D. Raney, Simultaneous binding to the tracking strand, displaced strand and the duplex of a DNA fork enhances unwinding by Dda helicase, Nucleic Acids Res. 42 (2014), pp. 11707–11720. doi:https://doi.org/10.1093/nar/gku845.
   PubMed Web of Science ®Google Scholar
• J. Xia, L.T. Chen, Q. Mei, C.H. Ma, J.A. Halliday, H.Y. Lin, D. Magnan, J.P. Pribis, D.M. Fitzgerald, H.M. Hamilton, M. Richters, R.B. Nehring, X. Shen, L. Li, D. Bates, P.J. Hastings, C. Herman, M. Jayaram, and S.M. Rosenberg, Holliday junction trap shows how cells use recombination and a junction-guardian role of RecQ helicase, Sci. Adv. 2 (2016), pp. e1601605. doi:https://doi.org/10.1126/sciadv.1601605.
   PubMed Web of Science ®Google Scholar
• B. Bartholomew, ISWI chromatin remodeling: One primary actor or a coordinated effort?, Curr. Opin. Struct. Biol. 24 (2014), pp. 150–155. doi:https://doi.org/10.1016/j.sbi.2014.01.010.
   PubMed Web of Science ®Google Scholar
• L. Subissi, I. Imbert, F. Ferron, A. Collet, B. Coutard, E. Decroly, and B. Canard, SARS-CoV ORF1b-encoded nonstructural proteins 12-16: Replicative enzymes as antiviral targets, Antiviral Res. 101 (2014), pp. 122–130. doi:https://doi.org/10.1016/j.antiviral.2013.11.006.
   PubMed Web of Science ®Google Scholar
• E. Prentice, J. McAuliffe, X. Lu, K. Subbarao, and M.R. Denison, Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins, J. Virol. 78 (2004), pp. 9977–9986. doi:https://doi.org/10.1128/JVI.78.18.9977-9986.2004.
   PubMed Web of Science ®Google Scholar
• S. Habtemariam, S.F. Nabavi, M. Banach, I. Berindan-Neagoe, K. Sarkar, P.C. Sil, and S.M. Nabavi, Should we try SARS-CoV-2 helicase inhibitors for COVID-19 therapy?, Arch. Med. Res. 51 (2020), pp. 733–735. doi:https://doi.org/10.1016/j.arcmed.2020.05.024.
   PubMed Web of Science ®Google Scholar
• X. Hu, W. Hao., B. Qin, Z. Tian, Z. Li, P. Hou, R. Zhao, S. Cui, and J. Diao, Mechanism of duplex unwinding by coronavirus nsp13 helicases, bioRxiv (2020). 08.02.233510.
   Google Scholar
• A.O. Adedeji, B. Marchand, A.J. Te Velthuis, E.J. Snijder, S. Weiss, R.L. Eoff, K. Singh, and S.G. Sarafianos, Mechanism of nucleic acid unwinding by SARS-CoV helicase, PloS One 7 (2012), pp. e36521. doi:https://doi.org/10.1371/journal.pone.0036521.
   PubMed Web of Science ®Google Scholar
• A.B. Gurung, In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors, Gene Rep. 21 (2020), pp. 100860. doi:https://doi.org/10.1016/j.genrep.2020.100860.
   PubMed Web of Science ®Google Scholar
• W. Hao, J.A. Wojdyla, R. Zhao, R. Han, R. Das, I. Zlatev, M. Manoharan, M. Wang, and S. Cui, Crystal structure of Middle East respiratory syndrome coronavirus helicase, PLoS Pathog. 13 (2017), pp. e1006474. doi:https://doi.org/10.1371/journal.ppat.1006474.
   PubMed Web of Science ®Google Scholar
• Z. Jia, L. Yan, Z. Ren, L. Wu, J. Wang, J. Guo, L. Zheng, Z. Ming, L. Zhang, Z. Lou, and Z. Rao, Delicate structural coordination of the Severe Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysis, Nucleic Acids Res. 47 (2019), pp. 6538–6550. doi:https://doi.org/10.1093/nar/gkz409.
   PubMed Web of Science ®Google Scholar
• J.A. Newman, Y. Yosaatmadja, A. Douangamath, C.H. Arrowsmith, F. von Delft, A. Edwards, C. Bountra, and O. Gileadi, Crystal structure of the SARS-CoV-2 helicase at 1.94 Angstrom resolution, Protein Data Bank (2020). doi:https://doi.org/10.2210/pdb6ZSL/pdb.
   Google Scholar
• O.M. Ugurel, O. Mutlu, E. Sariyer, S. Kocer, E. Ugurel, T.G. Inci, O. Ata, and D. Turgut-Balik, Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13), Int. J. Biol. Macromol. 163 (2020), pp. 1687–1696. doi:https://doi.org/10.1016/j.ijbiomac.2020.09.138.
   PubMed Web of Science ®Google Scholar
• M.A. White, W. Lin, and X. Cheng, Discovery of COVID-19 inhibitors targeting the SARS-CoV-2 Nsp13 helicase, J. Phys. Chem. Lett. 11 (2020), pp. 9144–9151. doi:https://doi.org/10.1021/acs.jpclett.0c02421.
   PubMed Web of Science ®Google Scholar
• M.U. Mirza and M. Froeyen, Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase, J. Pharm. Anal. 10 (2020), pp. 320–328. doi:https://doi.org/10.1016/j.jpha.2020.04.008.
   PubMed Web of Science ®Google Scholar
• C. Gorgulla, K.M. Padmanabha Das, K.E. Leigh, M. Cespugli, P.D. Fischer, Z.F. Wang, G. Tesseyre, S. Pandita, A. Shnapir, A. Calderaio, M. Gechev, A. Rose, N. Lewis, C. Hutcheson, E. Yaffe, R. Luxenburg, H.D. Herce, V. Durmaz, T.D. Halazonetis, K. Fackeldey, J.J. Patten, A. Chuprina, I. Dziuba, A. Plekhova, Y. Moroz, D. Radchenko, O. Tarkhanova, I. Yavnyuk, C. Gruber, R. Yust, D. Payne, A.M. Näär, M.N. Namchuk, R.A. Davey, G. Wagner, J. Kinney, and H. Arthanari, A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening, iScience 24 (2021), pp. 102021. doi:https://doi.org/10.1016/j.isci.2020.102021.
   PubMed Web of Science ®Google Scholar
• S. Khater and G. Das, Repurposing Ivermectin to inhibit the activity of SARS CoV2 helicase: Possible implications for COVID 19 therapeutics, OSF Preprints (2020), pp. 1–17.
   Google Scholar
• M.R. Freidel and R.S. Armen, Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase, PloS One 16 (2021), pp. e0246181. doi:https://doi.org/10.1371/journal.pone.0246181.
   PubMed Web of Science ®Google Scholar
• M.S. Yu, J. Lee, J.M. Lee, Y. Kim, Y.W. Chin, J.G. Jee, Y.S. Keum, and Y.J. Jeong, Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13, Bioorg. Med. Chem. Lett. 22 (2012), pp. 4049–4054. doi:https://doi.org/10.1016/j.bmcl.2012.04.081.
   PubMed Web of Science ®Google Scholar
• A.O. Adedeji, K. Singh, N.E. Calcaterra, M.L. DeDiego, L. Enjuanes, S. Weiss, and S.G. Sarafianos, Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase, Antimicrob. Agents Chemother. 56 (2012), pp. 4718–4728. doi:https://doi.org/10.1128/AAC.00957-12.
   PubMed Web of Science ®Google Scholar
• A.O. Adedeji, K. Singh, A. Kassim, C.M. Coleman, R. Elliott, S.R. Weiss, M.B. Frieman, and S.G. Sarafianos, Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses, Antimicrob. Agents Chemother. 58 (2014), pp. 4894–4898. doi:https://doi.org/10.1128/AAC.02994-14.
   PubMed Web of Science ®Google Scholar
• N.H. Zaher, M.I. Mostafa, and A.Y. Altaher, Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors, Acta Pharma. 70 (2020), pp. 145–159. doi:https://doi.org/10.2478/acph-2020-0024.
   PubMed Web of Science ®Google Scholar
• N. Mehyar, A. Mashhour, I. Islam, S. Gul, A.O. Adedeji, A.S. Askar, and M. Boudjelal, Using in silico modelling and FRET-based assays in the discovery of novel FDA-approved drugs as inhibitors of MERS-CoV helicase, SAR QSAR Environ. Res. 32 (2020), pp. 51–70. doi:https://doi.org/10.1080/1062936X.2020.1857437.
   Web of Science ®Google Scholar
• H.A. Alhadrami, A.M. Hassan, R. Chinnappan, H. Al-Hadrami, W.H. Abdulaal, E.I. Azhar, and M. Zourob, Peptide substrate screening for the diagnosis of SARS-CoV-2 using fluorescence resonance energy transfer (FRET) assay, Mikrochim. Acta 188 (2021), pp. 137. doi:https://doi.org/10.1007/s00604-021-04766-5.
   PubMed Web of Science ®Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet], National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD), (2012)-. Zafirlukast. [Updated 2019 June 4]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK547915/
   Google Scholar
• J. Zeng, F. Weissmann, A.P. Bertolin, V. Posse, B. Canal, R. Ulferts, M. Wu, R. Harvey, S. Hussain, J.C. Milligan, C. Roustan, A. Borg, L. McCoy, L.S. Drury, S. Kjaer, J. McCauley, M. Howell, R. Beale, and J.F.X. Diffley, Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase, Biochem. J. 478 (2021), pp. 2405–2423. doi:https://doi.org/10.1042/BCJ20210201.
   PubMed Web of Science ®Google Scholar
• M.D. Ezgimen, N.H. Mueller, T. Teramoto, and R. Padmanabhan, Effects of detergents on the West Nile virus protease activity, Bioorg. Med. Chem. 17 (2009), pp. 3278–3282. doi:https://doi.org/10.1016/j.bmc.2009.03.050.
   PubMed Web of Science ®Google Scholar
• D. Reker, G.J.L. Bernardes, and T. Rodrigues, Computational advances in combating colloidal aggregation in drug discovery, Nat. Chem. 11 (2019), pp. 402–418. doi:https://doi.org/10.1038/s41557-019-0234-9.
   PubMed Web of Science ®Google Scholar
• Z. Molavi, S. Razi, S.A. Mirmotalebisohi, A. Adibi, S. Mameni, F. Karami, V. Niazi, Z. Niknam, M. Aliashrafi, M. Taheri, S. Ghafouri-Fard, S. Jeibouei, S. Mahdian, H. Zali, M.M. Ranjbar, and M. Yazdani, Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach, Biomed. Pharmacother. 138 (2021), pp. 111544. doi:https://doi.org/10.1016/j.biopha.2021.111544.
   PubMed Web of Science ®Google Scholar
• M. Delijewski and J. Haneczok, AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate, Med. Drug Discov. 9 (2021), pp. 100077. doi:https://doi.org/10.1016/j.medidd.2020.100077.
   PubMedGoogle Scholar
• C. Xu, Z. Ke, C. Liu, Z. Wang, D. Liu, L. Zhang, J. Wang, W. He, Z. Xu, Y. Li, Y. Yang, Z. Huang, P. Lv, X. Wang, D. Han, Y. Li, N. Qiao, and B. Liu, Systemic in silico screening in drug discovery for coronavirus disease (COVID-19) with an online interactive web server, J. Chem. Inf. Model. 60 (2020), pp. 5735–5745. doi:https://doi.org/10.1021/acs.jcim.0c00821.
   PubMed Web of Science ®Google Scholar
• E. Di Salvo, V. Patella, M. Casciaro, and S. Gangemi, The leukotriene receptor antagonist Montelukast can induce adverse skin reactions in asthmatic patients, Pulm. Pharmacol. Ther. 60 (2020), pp. 101875. doi:https://doi.org/10.1016/j.pupt.2019.101875.
   PubMed Web of Science ®Google Scholar
• S.J. Keam, K.A. Lyseng-Williamson, and K.L. Goa, Pranlukast: A review of its use in the management of asthma, Drugs 63 (2003), pp. 991–1019. doi:https://doi.org/10.2165/00003495-200363100-00005.
   PubMed Web of Science ®Google Scholar
• H.M. Al-Kuraishy, A.I. Al-Gareeb, Y.Q. Almulaiky, N. Cruz-Martins, and G. El-Saber Batiha, Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity, Eur. J. Pharmacol. 904 (2021), pp. 174196. doi:https://doi.org/10.1016/j.ejphar.2021.174196.
   PubMed Web of Science ®Google Scholar
• J. Barré, J.M. Sabatier, and C. Annweiler Cédric, Montelukast drug may improve COVID-19 prognosis: A review of evidence, Front. Pharmacol. 11 (2020), pp. 1344. doi:https://doi.org/10.3389/fphar.2020.01344.
   PubMed Web of Science ®Google Scholar
• M. Dey and R.K. Singh, Possible therapeutic potential of cysteinyl leukotriene receptor antagonist montelukast in treatment of SARS-CoV-2-induced COVID-19, Pharmacology 106 (2021), pp. 469–476. doi:https://doi.org/10.1159/000518359.
   PubMed Web of Science ®Google Scholar
• A.R. Khan, C. Misdary, N. Yegya-Raman, S. Kim, N. Narayanan, S. Siddiqui, P. Salgame, J. Radbel, F. Groote, C. Michel, J. Mehnert, C. Hernandez, T. Braciale, J. Malhotra, M.A. Gentile, and S.K. Jabbour, Montelukast in hospitalized patients diagnosed with COVID-19, J. Asthma (2021), PP. 1–7, Advance online publication. doi:https://doi.org/10.1080/02770903.2021.1881967.
   Google Scholar
• K. Imamura, Y. Sakurai, T. Enami, R. Shibukawa, Y. Nishi, A. Ohta, T. Shu, J. Kawaguchi, S. Okada, T. Hoenen, J. Yasuda, and H. Inoue, iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility, FEBS Open Bio. 11 (2021), pp. 1452–1464. doi:https://doi.org/10.1002/2211-5463.13153.
   PubMed Web of Science ®Google Scholar
• W.J. Calhoun, Summary of clinical trials with zafirlukast, Am. J. Respir Crit. Care Med. 157 (1998), pp. S238–S246. doi:https://doi.org/10.1164/ajrccm.157.6.mar6.
   Web of Science ®Google Scholar